PBYI

Puma Biotechnology Inc.

Healthcare


Presented:10/17/2014
Price:$222.83
Cap:$6.71B
Current Price:$2.85
Cap:$0.14B

Presented

Date10/17/2014
Price$222.83
Market Cap$6.71B
Ent Value$6.53B
P/E RatioN/A
Book Value$4.70
Div YieldN/A
Shares O/S30.12M
Ave Daily Vol550,000
Short Int6.19%

Current

Price$2.85
Market Cap$0.14B
Puma Biotechnology, Inc., a development stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of products to enhance cancer care. Its drug candidates include PB272 (neratinib (oral)) for the treatment of advanced breast cancer patients, non-small cell lung cancer patients, and patients with HER2 mutation-positive solid tumors; and PB272 (neratinib (intravenous)) for the treatment of advanced cancer patients. The company is also developing PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.

Publicly traded companies mentioned herein: Puma Biotechnology Inc (PBYI), Pfizer Inc (PFE), Roche Holding AG (ROG VX), Johnson & Johnson (JNJ)

Highlights

The presenter began by stating, ”Puma Biotech is one of the more controversial short positions I have ever been involved in.” He sees material downside risk for shareholders, but stressed that he is cognizant of management’s track record, and respects the caliber of shareholders [heavily] invested in the company. Significant questions around neratinib’s (PB272 / HKI-272) trial design, and uncertainty about its ultimate market penetration - if approved - suggest the risk/ reward setup is favorable for bears at this time.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.